X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.519
+0.022 (4.32%)
At close: Oct 30, 2024, 4:00 PM
0.515
-0.004 (-0.77%)
After-hours: Oct 30, 2024, 7:57 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $563.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $563.00K.
Revenue (ttm)
$563.00K
Revenue Growth
n/a
P/S Ratio
183.65
Revenue / Employee
$6,054
Employees
93
Market Cap
87.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 308.13M |
PetMed Express | 270.77M |
DBV Technologies | 13.81M |
Armata Pharmaceuticals | 3.72M |
Chimerix | 144.00K |
XFOR News
- 6 days ago - X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial - GlobeNewsWire